Pharvaris (PHVS) Stock Forecast & Price Target

Q: What analysts cover Pharvaris?

Pharvaris has been rated by research analysts at Citigroup , Citizens Jmp , HC Wainwright , Royal Bank Of Canada , UBS Group , Wedbush , Weiss Ratings , and Wolfe Research in the past 90 days.

$29.94 +0.08 (+0.25%)

As of 03:45 PM Eastern

Compare

Pharvaris - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Moderate Buy

Based on 13 Analyst Ratings

Sell
1

Hold
2

Buy
10

Based on 13 Wall Street analysts who have issued ratings for Pharvaris in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 13 analysts, 1 has given a sell rating, 2 have given a hold rating, and 10 have given a buy rating for PHVS.

Consensus Price Target

$49.18
64.30% Upside

According to the 13 analysts' twelve-month price targets for Pharvaris, the average price target is $49.18. The highest price target for PHVS is $74.00, while the lowest price target for PHVS is $30.00. The average price target represents a forecasted upside of 64.30% from the current price of $29.94.

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Get the Latest News and Ratings for PHVS and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Pharvaris and its competitors.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

PHVS Analyst Ratings Over Time

Type	Current Forecast 5/29/25 to 5/29/26	1 Month Ago 4/29/25 to 4/29/26	3 Months Ago 2/28/25 to 2/28/26	1 Year Ago 5/29/24 to 5/29/25
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	10 Buy rating(s)	11 Buy rating(s)	9 Buy rating(s)	3 Buy rating(s)
Hold	2 Hold rating(s)	2 Hold rating(s)	2 Hold rating(s)	0 Hold rating(s)
Sell	1 Sell rating(s)	1 Sell rating(s)	1 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$49.18	$42.73	$40.56	$40.67
Forecasted Upside	64.30% Upside	43.24% Upside	42.85% Upside	143.22% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Buy

PHVS Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

PHVS Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Pharvaris Stock vs. The Competition

Type	Pharvaris	Medical Companies	Broader Market
Consensus Rating Score	2.69	2.30	2.52
Consensus Rating	Moderate Buy	Hold	Moderate Buy
Predicted Upside	62.68% Upside	1,715.18% Upside	14.45% Upside
News Sentiment Rating	Neutral News See Recent PHVS News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export

Date	Brokerage	Analyst	Action	Rating	Price Target	Report Date Upside/Downside
5/13/2026	UBS Group 4 of 5 stars		Set Target		$74.00	+136.80%
5/13/2026	Citizens Jmp 4 of 5 stars	Jonathan Wolleben 4 of 5 stars	Lower Target	Market Outperform	$75.00 ➝ $74.00	+130.64%
4/21/2026	Weiss Ratings Not Rated		Reiterated Rating	Sell (D-)
4/15/2026	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Reiterated Rating	Buy
4/9/2026	Wolfe Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Andy Chen Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Initiated Coverage	Outperform	$42.00	+52.39%
4/7/2026	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Laura Chico Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Outperform	$41.00 ➝ $42.00	+48.04%
4/6/2026	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Brian Abrahams Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Outperform	$52.00 ➝ $51.00	+78.57%
3/3/2026	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Patrick R. Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Buy	$60.00	+119.26%
12/4/2025	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Justin Kim Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Outperform	$44.00 ➝ $50.00	+70.30%
12/4/2025	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Debjit Chattopadhyay Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Buy	$32.00 ➝ $39.00	+32.83%
Get the Latest News and Ratings for PHVS and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Pharvaris and its competitors with MarketBeat's FREE daily newsletter.
12/4/2025	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Matthew Harrison Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Overweight	$37.00 ➝ $41.00	+39.65%
12/4/2025	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Tazeen Ahmad Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Neutral	$27.00 ➝ $30.00	+2.18%
12/3/2025	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Set Target		$38.00	+29.43%
8/18/2025	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Upgrade	Strong Sell ➝ Hold
5/14/2025	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Steve Seedhouse Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Overweight	$28.00 ➝ $25.00	+62.97%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Friday at 03:46 PM ET.

PHVS Forecast - Frequently Asked Questions

According to the research reports of 13 Wall Street equities research analysts, the average twelve-month stock price forecast for Pharvaris is $49.18, with a high forecast of $74.00 and a low forecast of $30.00.

13 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Pharvaris in the last twelve months. There is currently 1 sell rating, 2 hold ratings and 10 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" PHVS shares.

According to analysts, Pharvaris's stock has a predicted upside of 64.30% based on their 12-month stock forecasts.

Pharvaris has been rated by research analysts at Citigroup, Citizens Jmp, HC Wainwright, Royal Bank Of Canada, UBS Group, Wedbush, Weiss Ratings, and Wolfe Research in the past 90 days.

Analysts like Pharvaris more than other "medical" companies. The consensus rating for Pharvaris is Moderate Buy while the average consensus rating for "medical" companies is Hold. Learn more on how PHVS compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With Pharvaris Recommendations

This page (NASDAQ:PHVS) was last updated on 5/29/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Pharvaris (PHVS) Stock Forecast & Price Target